Skip to main content
SpringerLink
Log in
Book cover

Gene Therapy of Cancer pp 577–592Cite as

c-myb Antisense Oligonucleotide Therapeutics for Hematologic Malignancies

  • Protocol

  • 587 Accesses

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 35))

Abstract

Although improved significantly, conventional treatment of hematologic malignancy remains inadequate for many patients. Novel treatment approaches could be useful if they would be more efficacious and less toxic. One such approach could involve the manipulation of genes critical for leukemic cell growth and survival.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Colman, A. (1990) Antisense strategies in cell and developmental biology. J. Cell Sci. 97, 399–409.

    PubMed  CAS  Google Scholar 

  2. Gewirtz, A., Sokol, D. L., and Ratajczak, M. (1998) Nucleic acid therapeutics: state of the art and future prospects. Blood 92, 712–736.

    PubMed  CAS  Google Scholar 

  3. Helene, C. and Toulme, J. (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 1049, 99–125.

    PubMed  CAS  Google Scholar 

  4. van der Krol, A. R., Mol, J. N. M., and Sruitje, A. R. (1988) Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. Bio-Techniques 6, 958–976.

    Google Scholar 

  5. Holt, J. T., Redner, R. L., and Nienhuis, A. W. (1988) An oligomer complementary to c-myc mRNA inhibits its proliferation of HL-60 cells and induces differentiation. Mol. CellBiol. 8, 963–973.

    CAS  Google Scholar 

  6. Ratajczak, M. Z., Hijiya, N., Catani, L., de Riel, K., Luger, S. M., McGlave, P., and Gewirtz, A. M. (1992) Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 80, 1956–1961.

    Google Scholar 

  7. Miller, A. D. (1992) Human gene therapy come of age. Nature 357, 455–460.

    Article  PubMed  CAS  Google Scholar 

  8. Bishop, J. M. (1991) Molecular themes in oncogenesis. Cell 64, 235–248.

    Article  PubMed  CAS  Google Scholar 

  9. Shen-Ong, G. L. C. (1990) The myb oncogene. Biochim. Biophys. Acta 1032, 39–52.

    PubMed  CAS  Google Scholar 

  10. Baluda, M. A. and Goetz, I. E. (1961) Morphological conversion of cell cultures by avian myeloblastosis virus. Virology 15, 185–199.

    Article  PubMed  CAS  Google Scholar 

  11. Moscovici, C. and Gazzolo, L. (1982) Transformation of hemopoietic cells and avian leukemia viruses, in Advances in Viral Oncology, vol. 1 (Oncogene Studies), Raven, New York, pp. 83–106.

    Google Scholar 

  12. Radka, K., Beug, H., Kornfeld, S., and Graf, T. (1982) Transformation of both erythroid and myeloid cells by E26, an avian leukemia virus that contains the mybgene. Cell 31, 643–653.

    Article  Google Scholar 

  13. Westin, E. H., Gorse, K. M., and Clarke, M. F. (1990) Alternative splicing of the human c-myb gene. Oncogene 5, 117–124.

    Google Scholar 

  14. Luscher, B. and Eisenman, R. N. (1990) New light on myc and myb. Part II. myb. Genes Dev. 4, 2235–2241.

    Article  CAS  Google Scholar 

  15. Sakura, H. C., Kanei-Ishii, T., Nakagoshi, H., Gonda, T. J., and Ishii, S. (1989) Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene. Proc. Natl. Acad. Sci. USA 86, 5758–5762.

    Article  PubMed  CAS  Google Scholar 

  16. Luscher, B., Christenson, E., Litchfield, D. W., Krebs, E. G., and Eisenman, R. N. (1990) Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation. Nature 344, 517–522.

    Article  PubMed  CAS  Google Scholar 

  17. Thompson, C. B., Challoner, P. B., Neiman, P. E., and Groudine, M. (1986) Expression of the c-myb proto-oncogene during cellular proliferation. Nature 319, 374–380.

    Article  PubMed  CAS  Google Scholar 

  18. Slamon, D. J., Boone, T. C., Murdock, D. C., Keith, D. F., Press, M. F., Larson, R. A., and Souza, L. M. (1986) Studies of the human c-myb gene and its product in human acute leuemias. Science 232, 347–350.

    Article  Google Scholar 

  19. Duprey, S. P. and Boettiger, D. (1985) Developmental regulation of c-myb in normal myeloid progenitor cells. Proc. Natl. Acad. Sci. USA 82, 6937–6941.

    Article  PubMed  CAS  Google Scholar 

  20. Doolite, R. F., Hunkapiller, M. W., Hood, L. E., DeVare, S. G., Robbins, K. C., Aaronson, S. A., and Antonaides, H. N. (1983) Simian sarcoma onc gene, v-sis, is derived from the gene (or genes) encodding a platelet derived growth factor. Science 221, 275–277.

    Article  Google Scholar 

  21. Sherr, C. J., Rettenmier, C. W., Sacca, R., Roussel, M. F., Liook, A. T., and Stanley, R. F. (1985) The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41, 665–676.

    Article  PubMed  CAS  Google Scholar 

  22. Majumder, S., Brown, K., Qui, F. H., and Besmer, P. (1988) c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol. Cell Biol. 8, 4896–903.

    PubMed  CAS  Google Scholar 

  23. Todokoro, K., Watson, R. J., Higo, H., Amanuma, H., Kuramochi, S., Yanagisawa, H., and Ikawa, Y. (1988) Down-regulation of c-myb gene expression is a prerequisite for erythropoietin-induced erythroid differentiation. Proc. Natl. Acad. Sci. USA 85, 8900–8904.

    Article  PubMed  CAS  Google Scholar 

  24. Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schreiner, C. M., Miller, T. A., et al. (1991) A functional c-myb is required for normal murine fetal hepatic hematopoiesis. Cell 65, 677–689.

    Article  PubMed  CAS  Google Scholar 

  25. Gewirtz, A. M. and Calabretta, B. (1988) A c-myb antisense oligodeoxynucleotide inhibits normal human hemaopoiesis in vitro. Science 242, 1303–1306.

    Article  PubMed  CAS  Google Scholar 

  26. Caracciolo, D., Venturelli, D., Valtieri, M., Peschle, C., Gewirtz, A. M., and Calabretta, B. (1990) Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis. J. Clin. Invest. 85, 55–61.

    Article  PubMed  CAS  Google Scholar 

  27. Anfossi, G., Gewirtz, A. M., and Calbretta, B. (1989) An oligomer complementary to c-myb encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl. Acad. Sci. USA 86, 3379–3383.

    Article  PubMed  CAS  Google Scholar 

  28. Calabretta, B., Sims, R. B., Valtieri, M., Caracciolo, D., Szczylik, C., Venturelli, D., et al. (1991) Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: An in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA 88, 2351–2355.

    Article  PubMed  CAS  Google Scholar 

  29. Uhlmann, E. and Peyman, A. (1990) Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90, 543–584.

    Article  CAS  Google Scholar 

  30. Zon, G. and Stec, W. J. (1991) Oligofdeoxynucleotides: pharmacological considerations, in Oligonucleotides and Analogues: A Practical Approach (Eckstein, F., ed.), Oxford Univ. Press, Oxford, pp. 87–108.

    Google Scholar 

  31. Eder, P. S., DeVine, R. J., Dagle, J. M., and Walder, J. A. (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3 exonuclease in plasms. Antisense Res. Dev. 1, 141–151.

    PubMed  CAS  Google Scholar 

  32. Howe, K. M., Reakes, C. F., and Watson, R. J. (1990) Characterization of the sequence-specific interaction of mouse c-myb protein with DNA. EMBOJ 9, 161–169.

    CAS  Google Scholar 

  33. Miller, P. S. (1989) Non-ionic antisense oligonucleotides, in Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (Cohen, J. S., ed.), CRC, Boca Raton, FL, pp. 79–95.

    Google Scholar 

  34. Stein, C. A. and Cohen, J. S. (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 48, 2959–2668.

    Google Scholar 

  35. Motoji, T., Takanashi, M., Fuchinour, M., Masuda, M., Oshimi, K., and Mizoguchi, H. (1989) Effect of recombinant GM-CSF and recombinant G-CSF on colony formation of blast progenitors ina cutew myeloblastic leukemia. Exp. Hematol. 17, 56–60.

    PubMed  CAS  Google Scholar 

  36. Ratajczak, M. Z., Kant, J. A., Luger, S. M., Hijiya, N., Zhang, J., Zon, G., and Gewirtz, A. M. (1992) In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 89, 11,823–11,827.

    Article  PubMed  CAS  Google Scholar 

  37. Rizzoli, V. and Mangoni, L. (1990) Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group. Prog. Clin. Biol. Res. 333, 21–36.

    PubMed  CAS  Google Scholar 

  38. McGlave, P. (1990) Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin. Hematol. 27, 23–30.

    PubMed  CAS  Google Scholar 

  39. Barnett, M. J., Eaves, A. C., and Phillips, G. L. (1990) An overview of bone marrow transplantation for chronic myeloid leukemia. CMAJ 143, 187–193.

    PubMed  CAS  Google Scholar 

  40. Dunbar, C. E. and Stewart, F. M. (1992) Separating the wheat from the chaff: selection of benign hematopoietic cells in chronic myeloid leukemia. Blood 79, 1107–1110.

    PubMed  CAS  Google Scholar 

  41. Verfaillie, C. M., Miller, W. J., Boylan, K., and McGlave, P. B. (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79, 1003–1007.

    PubMed  CAS  Google Scholar 

  42. Gewirtz, A. M., Luger, S., Sokol, D., Gowdin, B., Stadtmauer, E., Recio, A., and Ratajczak, M. (1996) Oligodeoxynucleotide therapeutics for human myelogenous leukemia: interim results (abstr.). Blood 88, 270a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Marrow Transplant Program, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

    Selina Luger

Authors
  1. Selina Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Wolfgang Walther  & Ulrike Stein  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Luger, S. (2000). c-myb Antisense Oligonucleotide Therapeutics for Hematologic Malignancies. In: Walther, W., Stein, U. (eds) Gene Therapy of Cancer. Methods in Molecular Medicine™, vol 35. Humana Press. https://doi.org/10.1385/1-59259-086-1:577

Download citation

  • DOI: https://doi.org/10.1385/1-59259-086-1:577

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-714-4

  • Online ISBN: 978-1-59259-086-5

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation